[
    {
        "file_name": "AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_DevelopmentAgreement.txt",
        "perturbation": [
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "Within [***] ([***]) days after the Effective Date of this Agreement, Aimmune shall issue to Xencor shares of Aimmune Common Stock (the \"Shares\") in accordance with that certain Stock Issuance Agreement, dated the date hereof, by and among Xencor and Aimmune (the \"Stock Issuance Agreement\"), and pay to Xencor by wire transfer of immediately available funds, into an account designated in writing by Xencor, an amount equal to five million Dollars ($5,000,000) (together with the issuance of the Shares, the \"Upfront Payment\"). The Upfront Payment shall be nonrefundable and noncreditable against any other payments due hereunder.",
                "changed_text": "Within [***] ([***]) days after the Effective Date of this Agreement, Aimmune shall issue to Xencor shares of Aimmune Common Stock (the \"Shares\") in accordance with that certain Stock Issuance Agreement, dated the date hereof, by and among Xencor and Aimmune (the \"Stock Issuance Agreement\"), and pay to Xencor by wire transfer of immediately available funds, into an account designated in writing by Xencor, an amount equal to five million Dollars ($5,000,000) (together with the issuance of the Shares, the \"Upfront Payment\"). The Upfront Payment shall be refundable and noncreditable against any other payments due hereunder.",
                "explanation": "Changing the 'nonrefundable' nature of the Upfront Payment to 'refundable' creates a direct contradiction, making it unclear whether the payment should be returned under certain conditions. This introduces uncertainty in enforcement.",
                "location": "Section 7.1"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "Aimmune shall pay to Xencor the one-time milestone payments described in this Section 7.2 following achievement (and only upon the first occurrence) of the corresponding milestone event for a Product. Aimmune shall promptly notify Xencor in writing of, but in no event later than [***] ([***]) days after, the achievement of each such milestone event with respect to a Product. Aimmune shall pay the applicable milestone payment by wire transfer of immediately available funds within [***] ([***]) days after the achievement (and only upon the first occurrence) of the applicable milestone event into an account designated by Xencor in writing. Each such milestone payment is nonrefundable and noncreditable against any other payments due hereunder.",
                "changed_text": "Aimmune shall pay to Xencor the one-time milestone payments described in this Section 7.2 following achievement (and only upon the first occurrence) of the corresponding milestone event for a Product. Aimmune shall promptly notify Xencor in writing of, but in no event later than [***] ([***]) days after, the achievement of each such milestone event with respect to a Product. Aimmune shall pay the applicable milestone payment by wire transfer of immediately available funds within [***] ([***]) days after the achievement (and only upon the first occurrence) of the applicable milestone event into an account designated by Xencor in writing. Each such milestone payment is refundable and noncreditable against any other payments due hereunder.",
                "explanation": "Changing the 'nonrefundable' nature of the Milestone Payment to 'refundable' creates a direct contradiction, making it unclear whether the payment should be returned under certain conditions. This introduces uncertainty in enforcement.",
                "location": "Section 7.2"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "On a Product-by-Product and country-by-country basis during the Royalty Term applicable to such Product and such country, Aimmune shall pay to Xencor the following royalties on Net Sales of Products, subject to Section 7.3.2:",
                "changed_text": "On a Product-by-Product and country-by-country basis during the Royalty Term applicable to such Product and such country, Aimmune may or may not pay to Xencor the following royalties on Net Sales of Products, subject to Section 7.3.2:",
                "explanation": "Changing the 'shall' to 'may or may not' creates a direct contradiction, making it unclear whether Aimmune is obligated to pay Xencor royalties on Net Sales of Products. This introduces uncertainty in enforcement.",
                "location": "Section 7.3.1"
            }
        ]
    }
]